Bosentan competes with the binding of ET-1 and other ET peptides to both ET-A and ET-B receptors, with a slightly higher affinity for ET-A receptors (Ki = 4.1-43 nM) than for ET-B receptors (Ki = 38-730 nM). Bosentan specifically antagonises ET receptors and does not bind to other receptors.